Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Bramanti, Stefania  [Clear All Filters]
2024
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AMaria, Cutini I, Dodero A, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024.
Lambri N, Longari G, Loiacono D, Brioso RCoimbra, Crespi L, Galdieri C, Lobefalo F, Reggiori G, Rusconi R, Tomatis S, et al. Deep learning-based optimization of field geometry for total marrow irradiation delivered with volumetric modulated arc therapy. Med Phys. 2024.
2023
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):106.
Leone G, Baldini V, Bramanti S, Crocchiolo R, Gattillo S, Ermini S, Giudice V, Ferrero I, Moscato T, Milani R, et al. Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel. Blood Transfus. 2023.
Nagler A, Labopin M, Blaise D, Raiola AMaria, Corral LLopez, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16(1):58.
Di Vito C, Coianiz N, Calvi M, Terzoli S, Zaghi E, Puccio S, Frigo A, Mariotti J, De Philippis C, Mannina D, et al. Persistence of KIR NK cells after haploidentical hematopoietic stem cell transplantation protects from human cytomegalovirus infection/reactivation. Front Immunol. 2023;14:1266051.
Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, et al. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of th. Hemasphere. 2023;7(7):e920.
Saraceni F, Labopin M, Raiola AM, Blaise D, Reményi P, Sorà F, Pavlu J, Bramanti S, Busca A, Berceanu A, et al. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7(10):e952.
Autore F, Bramanti S, Lessi F, Innocenti I, Galli E, Rocchi S, Ribolla R, Derudas D, Oliva S, Stefanoni P, et al. Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?. Haematologica. 2023.
2022
Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, Bramanti S, Maspero D, Morello L, Merli M, et al. Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. Br J Haematol. 2022.
Mariotti J, Magri F, Giordano L, De Philippis C, Sarina B, Mannina D, Taurino D, Santoro A, Bramanti S. EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
Mariotti J, Raiola AMaria, Evangelista A, Harbi S, Patriarca F, Carella MAngelo, Martino M, Risitano A, Busca A, Giaccone L, et al. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
Duléry R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S, Maisano V, Chabannon C, Malard F, Brissot E, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplant. 2022.
van Beek JJP, Puccio S, Di Vito C, De Paoli F, Zaghi E, Calvi M, Scarpa A, Peano C, Basso G, Cibella J, et al. Selected memory T cells infused post haploidentical hematopoietic stem cell transplantation persist and hyper-expand. Blood Adv. 2022.
2021
Bramanti S, De Philippis C, Bartoli A, Giordano L, Mariotti J, Sarina B, Mannina D, Valli V, De Gregori S, Roperti M, et al. Feasibility and efficacy of a PK-guided busulfan conditioning regimen for Allogeneic SCT with PTCY as GVHD prophylaxis in adult patients with hematologic malignancies. Transplant Cell Ther. 2021.
Castagna L, Valli V, Timofeeva I, Capizzuto R, Bramanti S, Mariotti J, De Philippis C, Sarina B, Mannina D, Giordano L, et al. Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. Transplant Cell Ther. 2021.
Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.
Sarina B, Mancosu P, Navarria P, Bramanti S, Mariotti J, De Philippis C, Clerici E, Franzese C, Mannina D, Valli V, et al. Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. Transplant Cell Ther. 2021.
2020
De Philippis C, Legrand-Izadifar F, Bramanti S, Giordano L, de Oca CMontes, Duléry R, Bouabdallah R, Granata A, Devillier R, Mariotti J, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020;4(7):1242-1249.
Mariotti J, Raiola AMaria, Evangelista A, Carella AMichele, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
2019
Bramanti S, Calafiore V, Longhi E, Mariotti J, Crespiatico L, Sarina B, De Philippis C, Nocco A, Santoro A, Castagna L. Donor specific anti-HLA antibodies (DSA) in Haploidentical stem cell transplantation with Post Transplant Cyclophosphamide: risk of graft failure, poor graft function and impact on outcomes. Biol Blood Marrow Transplant. 2019.
Autore F, Piccirillo N, Nozza A, Innocenti I, Putzulu R, Chiusolo P, Sora' F, Zini G, Bacigalupo A, Castagna L, et al. Peripheral blood hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at two haematological Italian centres. Biol Blood Marrow Transplant. 2019.
Mariotti J, Taurino D, Marino F, Bramanti S, Sarina B, Morabito L, De Philippis C, Di Vito C, Mavilio D, Carlo-Stella C, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2019.
2018
Cauchois R, Castagna L, Pagliardini T, Harbi S, Calmels B, Bramanti S, Granata A, Lemarie C, Maisano V, Legrand F, et al. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 cells. Br J Haematol. 2018.
2016
Crocchiolo R, Giordano L, Rimondo A, Bologna M, Sarina B, Morabito L, Bramanti S, Castagna L, Mineri R. Human Herpesvirus 6 replication predicts Cytomegalovirus reactivation after allogeneic stem cell transplantation from haploidentical donor. J Clin Virol. 2016;84:24-26.

Pages